IP Library › Granted Patent US 7,851,763
Granted Patent B2
US 7,851,763 · App. 12/622,623 · Granted Dec 14, 2010

Method for improving clinical data quality in positron emission tomography

Assignee: Siemens Medical Solutions USA, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,851,763
App. No.
12/622,623
Granted
Dec 14, 2010
Kind
B2
Abstract

A method for improving clinical data quality in Positron Emission Tomography (PET). The method provides for the processing of PET data to accurately and efficiently determine a data single-to-noise ratio (SNR) corresponding to each individual clinical patient scan, as a function of a singles rate in a PET scanner. The method relates an injected dose to the singles rate to determine SNR(D inj ),and provides an accurate estimate of a quantity proportional to SNR, similar in function to the SNR(D inj ). Knowledge of SNR(D inj ) permits determination of peak SNR, optimal dose, SNR deficit, dose deficit, and differential dose benefit. The patient dose is fractionated, with a small calibration dose given initially. After a short uptake, the patient is pre-scanned to determine T, S, and R. An optimal does is then determined and the remainder injected.

Claims (169)

1. A method for improving clinical data quality in Positron Emission Tomography (PET), said method comprising the steps of:

(a) injecting a patient with a calibration dose of a radiopharmaceutical, said calibration dose being a fractionated portion of a patient dose of the radiopharmaceutical;

(b) pre-scanning the patient;

(c) determining a trues rate (T pat );

(d) determining a scattered events rate (S pat );

(e) determining a randoms rate (R pat );

(f) determining a singles rate s pat meas ;

(g) determining an optimal dose of the radiopharmaceutical using T pat , S pat , R pat and s pat meas ;

(h) determining a remainder dose as a difference between said optimal dose and said calibration dose; and

(i) injecting said patient with said remainder dose.

2. The method of claim 1 wherein said step of determining a trues rate is performed by:

T

pat

⁡

(

s

)

=

T

pat

⁡

(

s

pat

meas

)

T

phant

⁡

(

s

pat

⁢

meas

)

⁢

T

phant

⁡

(

s

)

;

wherein said step of determining a randoms rate is performed by:

R

pat

⁡

(

s

)

=

R

pat

⁡

(

s

pat

meas

)

T

phant

⁡

(

s

pat

meas

)

⁢

T

phant

⁡

(

s

)

;

⁢

and

wherein said scattered events rate is included in determining said trues rate such that:

(

T

+

S

)

pat

⁢

(

s

)

=

(

T

+

S

)

pat

⁢

(

s

pat

meas

)

(

T

+

S

)

phant

⁢

(

s

pat

meas

)

⁢

(

T

+

S

)

phant

⁢

(

s

)

;

wherein s is a total measured singles rate.

3. The method of claim 2 wherein T(s) and R(s) are measured for a given scanner at at least one value of s using a phantom.

4. The method of claim 2 wherein T(s) closely approximates (T+S)(s) in shape and wherein (T+S) defines a net trues rate, wherein (T+S) is measured directly, and wherein said trues rate is estimated by subtracting an estimate of a mean scatter distribution.

5. The method of claim 2 wherein said randoms rate is estimated using one of a group of methods including at least estimating said randoms rate directly from a delayeds sonogram, estimating said randoms rate as a fraction of a total delayeds rate assuming a uniform distribution and using an attenuation mask, and estimating said randoms rate form a spatial distribution of said singles rates.

6. The method of claim 2 further including the step of estimating a single-to-noise ration (SNR) as a function of said singles rate.

7. The method of claim 6 further including the step of relating said calibration dose to said singles rate by calibrating a phantom measurement of activity compared to said singles rate for a single patient acquisition to determine a dose response curve as:

A

pat

⁡

(

s

)

=

A

pat

⁡

(

s

pat

means

)

A

phant

⁡

(

s

pat

Meas

)

⁢

A

phant

⁡

(

s

)

,

where A represents one of a total activity and a mean activity concentration per mass or volume.

8. The method of claim 7 wherein A is a monotonic function of s, wherein said calibration dose is related to A by a decay factor and excretion fraction, said method further comprising the step of substituting said calibration does for A.

9. The method of claim 1 further comprising the step of developing a database relating patient characteristics including at least weight, body mass index, sex, disease, diabetes state, and anatomical position to optimal dose and peak SNR.

10. The method of claim 9 further including the step of statistically correlating said optimal dose for each scan completed into said database.

11. The method of claim 9 further including the steps of:

(a) comparing said patient characteristics for a new patient with said database; and

(b) estimating said optimal dose for said new patient.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 24, 2010
From: BENDRIEM, BERNARD; CASEY, MICHAEL E; WATSON, CHARLES C.
To: SIEMENS MEDICAL SOLUTIONS USA, INC.
Reel/Frame 023983/0133 →
Continuity (1)
Related Publication 20100148047A1 · Jun 17, 2010